Ríos-Hoyo, AlejandroMoliner Jiménez, LauraArriola Aperribay, Edurne2022-10-142022-10-142022Ríos-Hoyo A, Moliner L, Arriola E. Acquired mechanisms of resistance to osimertinib-the next challenge. Cancers (Basel). 2022 Apr 12; 14(8): 1931. DOI: 10.3390/cancers140819312072-6694http://hdl.handle.net/10230/54397EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them.application/pdfengCopyright © 2022 by Ríos-Hoyo A, Moliner L, Arriola E. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/cancers14081931EGFRNSCLCMechanisms of resistanceOsimertinibinfo:eu-repo/semantics/openAccess